Nurix Therapeutics Announces Promising Clinical Data, Secures $15 Million License Fee, and Receives FDA Clearance for IRAK4 Degrader

Nurix Therapeutics reported Q1 FY25 financial results, with a net loss of $43.5mln, up from $44.5mln YoY, and R&D expenses increasing to $78.1mln from $48.9mln YoY. However, the company secured a $15mln license fee from Sanofi and received FDA clearance for a novel IRAK4 degrader in collaboration with Gilead. Nurix also presented updated data for bexobrutideg showing an 80.9% objective response rate in CLL patients and has a strong cash position of $485.8mln.

San Francisco, July 02, 2025 — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, reported its Q2 2025 financial results, highlighting significant progress across its clinical programs and strategic collaborations. The company delivered impressive clinical data for its lead asset, bexobrutideg (NX-5948), and secured a $15 million license fee from Sanofi's STAT6 collaboration extension. Additionally, Nurix received FDA clearance for its novel IRAK4 degrader, GS-6791/NX-0479, in collaboration with Gilead Sciences, Inc.

Financial Highlights

- Revenue: Q2 2025 revenue stood at $44.1 million, marking a substantial increase from $12.1 million in the same period last year.
- R&D Expenses: R&D expenses increased to $78.1 million from $48.9 million year-over-year, reflecting the company's ongoing investment in clinical trials and manufacturing.
- Cash Position: Nurix maintained a strong cash position of $485.8 million as of May 31, 2025, providing ample funding for future operations and clinical trials.
- Net Loss: The company reported a net loss of $43.5 million, down from $44.5 million in the same period last year.

Clinical Milestones

- Bexobrutideg (NX-5948): Updated data for bexobrutideg presented an impressive 80.9% objective response rate in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The favorable safety profile, with no atrial fibrillation or systemic fungal infections, supports advancement to pivotal trials.
- GS-6791/NX-0479: FDA clearance of the IND for GS-6791/NX-0479, an IRAK4 degrader, enables Gilead to initiate Phase 1 trials. This collaboration expands Nurix's inflammation portfolio.

Strategic Collaborations

- Sanofi's STAT6 Program: The extension of Sanofi's license for the STAT6 program triggered a $15 million payment, bringing total collaboration payments to $127 million with potential for additional milestones and royalties.
- Gilead Sciences: The collaboration with Gilead for the development of GS-6791/NX-0479 represents a significant milestone in Nurix's inflammation portfolio.

Conclusion

Nurix Therapeutics has delivered a compelling quarter marked by promising clinical data and strategic collaboration milestones. The company's strong cash position and continued investment in R&D position it well for future clinical trials and market expansion. With a differentiated approach to targeted protein degradation across oncology and immunology, Nurix is at the forefront of this emerging therapeutic modality.

References

[1] https://www.stocktitan.net/news/NRIX/nurix-therapeutics-reports-second-quarter-2025-financial-results-and-2n21j8f1o40e.html